IMMUNEONCO-B (01541) has announced the successful administration of the first dose in its Phase II randomized and placebo-controlled clinical trial evaluating IMM0306 for the treatment of systemic lupus erythematosus (SLE). The trial is expected to enroll approximately 90 patients, who will be randomly assigned in a 1:1:1 ratio to one of three treatment groups. These groups will receive either IMM0306 at doses of 1.2 mg/kg or 1.6 mg/kg, or a placebo.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.